Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.

× No keyword cloud information.

20 in total

1. Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.

Authors: Lisa A Bonner; Benjamin R Chemel; Val J Watts; David E Nichols
Journal: Bioorg Med Chem Date: 2010-07-27 Impact factor: 3.641

Review 2. GPCR functional selectivity has therapeutic impact.

Authors: Richard B Mailman
Journal: Trends Pharmacol Sci Date: 2007-07-13 Impact factor: 14.819

3. Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

Authors: Juan Pablo Cueva; Alejandra Gallardo-Godoy; Jose I Juncosa; Pierre A Vidi; Markus A Lill; Val J Watts; David E Nichols
Journal: J Med Chem Date: 2011-07-14 Impact factor: 7.446

4. SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors: Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal: Neuropharmacology Date: 2014-06-12 Impact factor: 5.250

5. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

Authors: Juan Pablo Cueva; Benjamin R Chemel; Jose I Juncosa; Markus A Lill; Val J Watts; David E Nichols
Journal: Eur J Med Chem Date: 2011-12-03 Impact factor: 6.514

6. Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Authors: Alia H Clark; John D McCorvy; Val J Watts; David E Nichols
Journal: Bioorg Med Chem Date: 2011-08-03 Impact factor: 3.641

Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.

1. Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.

Review 2. GPCR functional selectivity has therapeutic impact.

3. Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

4. SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

5. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

6. Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Review 7. Brain dopamine receptors: 20 years of progress.

8. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Review 9. Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Review 10. Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.